{
    "clinical_study": {
        "@rank": "29909", 
        "acronym": "CORTICOIDOSE", 
        "arm_group": [
            {
                "arm_group_label": "oral prednisone", 
                "arm_group_type": "No Intervention", 
                "description": "Oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12."
            }, 
            {
                "arm_group_label": "methylprednisolone bolus", 
                "arm_group_type": "Experimental", 
                "description": "methylprednisolone bolus 15 mg/kg/d for 3 days before oral prednisone 1 mg/kg/d for 30 days and progressive tapering of steroids, to get 0,5 mg/kg/d at M3 and 0,25 mg/kg/d at M6 and 5-10 mg at M12."
            }
        ], 
        "brief_summary": {
            "textblock": "Renal sarcoidosis treatment is based on steroids, but the dose and duration are unknown.\n      Despite this treatment, most patients will have chronic kidney disease. From our previous\n      studies, the investigators believe that high dose steroids by methylprednisolone bolus will\n      improve patient outcome and renal function."
        }, 
        "brief_title": "Treatment of Renal Sarcoidosis by Methylprednisolone Bolus", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Renal Sarcoidosis", 
        "condition_browse": {
            "mesh_term": "Sarcoidosis"
        }, 
        "detailed_description": {
            "textblock": "In a multicentric, randomized, open trial, the investigators will assess the efficacy of\n      methylprednisolone bolus at 15mg/kg/d for 3 days before oral steroids on renal function\n      improvement in renal sarcoidosis patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18 years\n\n          -  Acute kidney injury with estimated glomerular filtration rate (eGFR) < 60 mL/min/1,73\n             m2, defined by an increase of initial value > 25% or an increase of > 30 \u00b5mol/l,\n             since at least 3 months.\n\n          -  Sarcoidosis diagnostic criteria according to ATS/ERS/WASOG (Am J Respir Crit Care Med\n             1999)\n\n          -  Renal biopsy compatible with renal sarcoidosis :\n\n          -  Granulomatosis tubulo-interstitial nephropathy and extra-renal damage of\n             histologically proved or suggestive sarcoidosis Or\n\n          -  Tubulo-interstitial nephropathy without granuloma and extra-renal damage of\n             histologically proved sarcoidosis\n\n          -  Informed consent\n\n          -  Patients with social security\n\n        Exclusion Criteria:\n\n          -  Corticosteroids greater than 0,25 mg/kg/j prednisone equivalent\n\n          -  Introduction of an immunosuppressant in the month before inclusion\n\n          -  Another cause of renal granulomatosis or tubulo-interstitial nephropathy\n\n          -  Isolated renal damage without extra-renal past or present damage for a sarcoidosis\n\n          -  Chronic renal failure, prior sarcoidosis with eGFR < 30 mL/min/1,73 m2\n\n          -  Acute renal failure from other causes. If hypercalcaemia is greater than 3 mmol/L,\n             the correction of any dehydration will systematically salt intake, followed of renal\n             function control before inclusion.\n\n          -  Pregnancy, nursing\n\n          -  Tuberculosis\n\n          -  Uncontrolled sepsis\n\n          -  Uncontrolled psychotic state\n\n          -  Hypersensibility to methylprednisolone hemisuccinate\n\n          -  Drugs prescription causing wave burst arrhythmia and/or long QT on ECG"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01652417", 
            "org_study_id": "P 110118", 
            "secondary_id": "AOM 11003"
        }, 
        "intervention": {
            "arm_group_label": "methylprednisolone bolus", 
            "description": "methylprednisolone bolus IV 15 mg/kg/d for 3 days.", 
            "intervention_name": "methylprednisolone bolus IV 15 mg/kg/d for 3 days.", 
            "intervention_type": "Drug", 
            "other_name": "Methylprenisolone Mylan"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Methylprednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone", 
                "Prednisone", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Methylprednisolone", 
            "prednisone", 
            "renal sarcoidosis treatment"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "contact": {
                "last_name": "Jean-Jacques Boffa, PU-PH"
            }, 
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France"
                }, 
                "name": "Service de N\u00e9phrologie et Dialyses, H\u00f4pital Tenon"
            }, 
            "investigator": {
                "last_name": "Jean-Jacques Boffa, PU-PH", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Multicentric Study Evaluating the Efficacy and the Safety of Methylprednisolone Bolus in the Treatment of Renal Sarcoidosis", 
        "overall_contact": {
            "email": "jean-jacques.boffa@tnn.aphp.fr", 
            "last_name": "Jean-Jacques Boffa, PU-PH", 
            "phone": "+ 33 (0) 1 56 01 60 29"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
                "France: French Data Protection Authority"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of patients with a positive response defined by eGRF better than 100% compared to eGRF prior treatment or a normalization of renal function.", 
            "safety_issue": "No", 
            "time_frame": "3 months after the beginning of the treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01652417"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Efficacy (eGFR, percentage of patients with a eGRF < 60 ml/min/1.73m\u00b2)", 
                "safety_issue": "No", 
                "time_frame": "1, 3, 6 and 12 months after the beginning of the treatment"
            }, 
            {
                "measure": "Extra-renal manifestations", 
                "safety_issue": "Yes", 
                "time_frame": "1, 3, 6 and 12 months after the beginning of the treatment"
            }, 
            {
                "measure": "incidence of arrhythmias and cardiac conduction disease", 
                "safety_issue": "Yes", 
                "time_frame": "1, 3, 6 and 12 months after the beginning of the treatment"
            }, 
            {
                "measure": "fragility fracture", 
                "safety_issue": "Yes", 
                "time_frame": "1, 3, 6 and 12 months after the beginning of the treatment"
            }, 
            {
                "measure": "neuro-psychiatric troubles and infections", 
                "safety_issue": "Yes", 
                "time_frame": "1, 3, 6 and 12 months after the beginning of the treatment"
            }, 
            {
                "measure": "number of renal and extra-renal relapses.", 
                "safety_issue": "Yes", 
                "time_frame": "1, 3, 6 and 12 months after the beginning of the treatment"
            }, 
            {
                "measure": "Characterization of vitamin and calcium deficiencies by blood and urinary dosages", 
                "safety_issue": "Yes", 
                "time_frame": "1, 3, 6 and 12 months after the beginning of the treatment"
            }
        ], 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}